Bone health trends
Amgen’s (AMGN) leading bone health drug, Prolia, reported revenue of $592 million in the first quarter, a YoY (year-over-year) rise of 20% driven by 17% YoY volume growth. The drug is approved for postmenopausal women with osteoporosis and a high risk of fracture, for cancer-treatment-induced bone loss, for bone loss in men with osteoporosis and a high risk of fracture, and for glucocorticoid-induced osteoporosis. According to Amgen’s first-quarter earnings call, owing to its six-month dosing interval, Prolia’s sales in the first and third quarters are generally lower than those in the second and fourth quarters of the year.
On April 9, the FDA approved Evenity, a drug that’s capable of aiding bone formation while reducing bone loss, to treat osteoporosis in postmenopausal women who are at a high risk of fracture. The drug was commercially launched in the US with a list price of $21,900 for the full treatment course of 12 doses. Evenity is also approved in Japan and is being launched there via a joint venture with Astellas Pharma.
In the first quarter, Amgen’s oncology drugs Xgeva, Nplate, Vectibix, Kyprolis, Imlygic, and Blincyto reported a combined $1.2 billion in revenue, up 8% YoY.
In the first quarter, Kyprolis, Amgen’s multiple myeloma drug, reported revenue of $154 million, a YoY rise of 10%. The drug’s once-a-week dosing regimen accounts for almost 20% of its usage in the US. Amgen’s Xgeva reported revenue of $471 million, a rise of 6% YoY.
Blincyto’s sales rose 41% YoY to $69 million in the first quarter. According to its first-quarter earnings call, Amgen is also studying Blincyto in combination with PD-1 inhibitors in various indications.
One of the highly watched investigational therapies in Amgen’s R&D pipeline is AMG 510, the first KRASG12C Inhibitor in the clinical testing phase. The company presented promising data from its Phase 1 trial evaluating this therapy in non-small cell lung cancer and colorectal cancer indications at an American Society of Clinical Oncology meeting.